普拉克索
分裂情感障碍
阳性与阴性症状量表
精神分裂症(面向对象编程)
安慰剂
心理学
随机对照试验
精神科
内科学
全球功能评估
锥体外系症状
抗精神病药
医学
精神病
帕金森病
疾病
替代医学
病理
作者
Linda Levi,Daisy Zamora,Igor Nastas,Ilan Gonen,Paull Radu,Valentin Matei,Adela Magdalena Ciobanu,Anatol Nacu,Larisa Boronin,Lusian Karakrah,Michael Davidson,John M. Davis,Mark Weiser
摘要
Objective: Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. A confirmatory trial was conducted to test this hypothesis. Methods: This 16-week, multicenter, double-blind, randomized, placebo-controlled study included 200 subjects meeting DSM-IV-TR criteria for schizophrenia or schizoaffective disorder. Patients were randomized to receive either pramipexole (0.75 mg twice daily, n = 100) or placebo (n = 100) as an add-on to their regular antipsychotic treatment. The primary outcome measure was the total score on the Positive and Negative Syndrome Scale (PANSS); secondary outcome measures included PANSS subscale and cognitive functioning scores. Recruitment was performed in 30 sites in Romania and 1 site in the Republic of Moldova between January and June 2011. Results: Analysis of covariance models showed no significant difference between pramipexole and placebo for total PANSS (P > .99) and PANSS positive (P > .99), negative (P = .73), and general psychopathology (P = .99) subscale scores. Changes in Clinical Global Impressions–Severity of Illness scale and Brief Assessment of Cognition in Schizophrenia scores showed no significant difference between pramipexole and placebo. Conclusions: The results of this large randomized controlled trial indicated that pramipexole was not efficacious as an add-on to antipsychotic medications for schizophrenia. Trial Registration: ClinicalTrials.gov identifier NCT01320982
科研通智能强力驱动
Strongly Powered by AbleSci AI